BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

575 related articles for article (PubMed ID: 32020559)

  • 1. Investigating Overlap in Signals from EVDAS, FAERS, and VigiBase
    Vogel U; van Stekelenborg J; Dreyfus B; Garg A; Habib M; Hosain R; Wisniewski A
    Drug Saf; 2020 Apr; 43(4):351-362. PubMed ID: 32020559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An experimental investigation of masking in the US FDA adverse event reporting system database.
    Wang HW; Hochberg AM; Pearson RK; Hauben M
    Drug Saf; 2010 Dec; 33(12):1117-33. PubMed ID: 21077702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of the MedDRA hierarchy on pharmacovigilance data mining results.
    Pearson RK; Hauben M; Goldsmith DI; Gould AL; Madigan D; O'Hara DJ; Reisinger SJ; Hochberg AM
    Int J Med Inform; 2009 Dec; 78(12):e97-e103. PubMed ID: 19230751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reducing the noise in signal detection of adverse drug reactions by standardizing the background: a pilot study on analyses of proportional reporting ratios-by-therapeutic area.
    Grundmark B; Holmberg L; Garmo H; Zethelius B
    Eur J Clin Pharmacol; 2014 May; 70(5):627-35. PubMed ID: 24599513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An evaluation of three signal-detection algorithms using a highly inclusive reference event database.
    Hochberg AM; Hauben M; Pearson RK; O'Hara DJ; Reisinger SJ; Goldsmith DI; Gould AL; Madigan D
    Drug Saf; 2009; 32(6):509-25. PubMed ID: 19459718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Contribution of National Spontaneous Reporting Systems to Detect Signals of Torsadogenicity: Issues Emerging from the ARITMO Project.
    Raschi E; Poluzzi E; Salvo F; Koci A; Suling M; Antoniazzi S; Perina L; Hazell L; Moretti U; Sturkenboom M; Garbe E; Pariente A; De Ponti F
    Drug Saf; 2016 Jan; 39(1):59-68. PubMed ID: 26446144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems.
    Raschi E; Parisotto M; Forcesi E; La Placa M; Marchesini G; De Ponti F; Poluzzi E
    Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1098-1107. PubMed ID: 29174026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of Disproportionality Analysis to Identify Previously Unknown Drug-Associated Causes of Cardiac Arrhythmias Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
    Moreland-Head LN; Coons JC; Seybert AL; Gray MP; Kane-Gill SL
    J Cardiovasc Pharmacol Ther; 2021 Jul; 26(4):341-348. PubMed ID: 33403858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of Perflutren Ultrasound Contrast Agents: A Disproportionality Analysis of the US FAERS Database.
    Hauben M; Hung EY; Hanretta KC; Bangalore S; Snow V
    Drug Saf; 2015 Nov; 38(11):1127-39. PubMed ID: 26242615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel Adverse Events of Iloperidone: A Disproportionality Analysis in US Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
    Subeesh V; Maheswari E; Singh H; Beulah TE; Swaroop AM
    Curr Drug Saf; 2019; 14(1):21-26. PubMed ID: 30362421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ADEpedia-on-OHDSI: A next generation pharmacovigilance signal detection platform using the OHDSI common data model.
    Yu Y; Ruddy KJ; Hong N; Tsuji S; Wen A; Shah ND; Jiang G
    J Biomed Inform; 2019 Mar; 91():103119. PubMed ID: 30738946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
    Welch HK; Kellum JA; Kane-Gill SL
    Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pilot evaluation of an automated method to decrease false-positive signals induced by co-prescriptions in spontaneous reporting databases.
    Avillach P; Salvo F; Thiessard F; Miremont-Salamé G; Fourrier-Reglat A; Haramburu F; Bégaud B; Moore N; Pariente A;
    Pharmacoepidemiol Drug Saf; 2014 Feb; 23(2):186-94. PubMed ID: 23670805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse event profiles of ifosfamide-induced encephalopathy analyzed using the Food and Drug Administration Adverse Event Reporting System and the Japanese Adverse Drug Event Report databases.
    Shimada K; Hasegawa S; Nakao S; Mukai R; Matsumoto K; Tanaka M; Uranishi H; Masuta M; Nishida S; Shimizu S; Hayashi Y; Suzuki A; Nakamura M
    Cancer Chemother Pharmacol; 2019 Nov; 84(5):1097-1105. PubMed ID: 31502115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib.
    Peng L; Xiao K; Ottaviani S; Stebbing J; Wang YJ
    Expert Opin Drug Saf; 2020 Nov; 19(11):1505-1511. PubMed ID: 32693646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Profiling cumulative proportional reporting ratios of drug-induced liver injury in the FDA Adverse Event Reporting System (FAERS) database.
    Brinker AD; Lyndly J; Tonning J; Moeny D; Levine JG; Avigan MI
    Drug Saf; 2013 Dec; 36(12):1169-78. PubMed ID: 24178291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of Disproportionality Analysis of Pharmacovigilance Databases in Safety Regulatory Actions: a Systematic Review.
    Dias P; Penedones A; Alves C; Ribeiro CF; Marques FB
    Curr Drug Saf; 2015; 10(3):234-50. PubMed ID: 26219291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Natural Language Processing (NLP) systems to annotate drug product labeling with MedDRA terminology.
    Ly T; Pamer C; Dang O; Brajovic S; Haider S; Botsis T; Milward D; Winter A; Lu S; Ball R
    J Biomed Inform; 2018 Jul; 83():73-86. PubMed ID: 29860093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of anticholinergic adverse effects using two large databases: The US Food and Drug Administration Adverse Event Reporting System database and the Japanese Adverse Drug Event Report database.
    Nagai J; Ishikawa Y
    PLoS One; 2021; 16(12):e0260980. PubMed ID: 34855908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular safety signals with dipeptidyl peptidase-4 inhibitors: A disproportionality analysis among high-risk patients.
    Baksh SN; McAdams-DeMarco M; Segal JB; Alexander GC
    Pharmacoepidemiol Drug Saf; 2018 Jun; 27(6):660-667. PubMed ID: 29655237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.